Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Prostate Cancer

  Free Subscription


Articles published in Urol Int

Retrieve available abstracts of 41 articles:
HTML format



Single Articles


    November 2022
  1. SOTOMAYOR PC, Aguilar JC, Mujica K, Zuniga A, et al
    Active Surveillance in Prostate Cancer: Current and Potentially Emerging Biomarkers for Patient Selection Criteria.
    Urol Int. 2022 Nov 7:1-13. doi: 10.1159/000527151.
    PubMed     Abstract available


    October 2022
  2. BORKOWETZ A, Linxweiler J, Fussek S, Wullich B, et al
    The Role of PSMA PET Imaging in Prostate Cancer Theranostics: A Nationwide Survey.
    Urol Int. 2022 Oct 4:1-10. doi: 10.1159/000526598.
    PubMed     Abstract available


    March 2022
  3. WU J, Wei Y, Li T, Lin L, et al
    DNA Methylation-Mediated Lowly Expressed AOX1 Promotes Cell Migration and Invasion of Prostate Cancer.
    Urol Int. 2022 Mar 30:1-9. doi: 10.1159/000522634.
    PubMed     Abstract available


  4. MAKINO K, Sato Y, Takenaka R, Yamashita H, et al
    Cumulative Incidence and Clinical Risk Factors of Radiation Cystitis after Radiotherapy for Prostate Cancer.
    Urol Int. 2022 Mar 15:1-7. doi: 10.1159/000521723.
    PubMed     Abstract available


  5. HIGASHIYAMA S, Yoshida A, Kawabe J
    Predicting the Prognosis of Prostate Cancer Bone Metastasis Using the Bone Scan Index and Hot Spots Calculated Using VSBONE Bone Scan Index from Tc-99m-Hydroxymethylene Diphosphonate Bone Scintigraphy.
    Urol Int. 2022 Mar 4:1-7. doi: 10.1159/000522046.
    PubMed     Abstract available


    February 2022
  6. JIN C, Bian Z, Mo F, Zhu C, et al
    Establishment and Validation of Coagulation Factor-Based Nomogram for Predicting the Recurrence-Free Survival of Prostate Cancer.
    Urol Int. 2022 Feb 18:1-9. doi: 10.1159/000519329.
    PubMed     Abstract available


  7. SOKMEN BK, Sokmen D, Comez YI, Eksi M, et al
    Prediction of Prostate Cancer Aggressiveness Using a Novel Multiparametric Magnetic Resonance Imaging Parameter: Tumor Heterogeneity Index.
    Urol Int. 2022 Feb 11:1-8. doi: 10.1159/000521606.
    PubMed     Abstract available


  8. BORKOWETZ A, Blana A, Bohmer D, Cash H, et al
    German S3 Evidence-Based Guidelines on Focal Therapy in Localized Prostate Cancer: The First Evidence-Based Guidelines on Focal Therapy.
    Urol Int. 2022 Feb 10:1-9. doi: 10.1159/000521882.
    PubMed     Abstract available


  9. CAFUTA B, Distler FA, Wagner A, Pahernik S, et al
    Salvage Radiotherapy for Recurrent Prostate Cancer after High-Intensity Focused Ultrasound Therapy: Quality of Life and Functional Outcome.
    Urol Int. 2022 Feb 1:1-6. doi: 10.1159/000521660.
    PubMed     Abstract available


    January 2022
  10. PORCARO AB, Panunzio A, Tafuri A, Cerrato C, et al
    The Influence of Endogenous Testosterone Density on Unfavorable Disease and Tumor Load at Final Pathology in Intermediate-Risk Prostate Cancer: Results in 338 Patients Treated with Radical Prostatectomy and Extended Pelvic Lymph Node Dissection.
    Urol Int. 2022 Jan 26:1-12. doi: 10.1159/000521260.
    PubMed     Abstract available


  11. HARLAND N, Russo GI, Kaufmann S, Amend B, et al
    Robotic Transrectal Computed Tomographic Ultrasound with Artificial Neural Network Analysis: First Validation and Comparison with MRI-Guided Biopsies and Radical Prostatectomy.
    Urol Int. 2022;106:90-96.
    PubMed     Abstract available


  12. WETTERAUER C, Federer-Gsponer JR, Leboutte FDJP, Mona R, et al
    Indication for Active Surveillance in the Era of MRI-Targeted Prostate Biopsies.
    Urol Int. 2022;106:83-89.
    PubMed     Abstract available


  13. HAEUSER L, Reese SW, Paciotti M, Noldus J, et al
    Surgical Complications Requiring Intervention in Open versus Minimally Invasive Radical Prostatectomy.
    Urol Int. 2022;106:51-55.
    PubMed     Abstract available


  14. PFISTER D, Nestler T, Hartmann F, Haidl F, et al
    Feasibility and Oncologic Outcome of Salvage Surgery in Isolated Seminal Vesicle Remnants after Radical Prostatectomy.
    Urol Int. 2022;106:44-50.
    PubMed     Abstract available


  15. DING XF, Luan Y, Xia AL, Zhu LY, et al
    Application of 16 G Biopsy Needle in Transperineal Template-Guided Prostate Biopsy.
    Urol Int. 2022;106:909-913.
    PubMed     Abstract available


  16. SONG JA, He BM, Li HS, Yu XW, et al
    A Prospective Study Comparing Cancer Detection Rates of Transperineal Prostate Biopsies Performed by Junior Urologists versus a Senior Consultant in a Real-World Setting.
    Urol Int. 2022;106:884-890.
    PubMed     Abstract available


  17. KOZARIS R, Hanske J, von Landenberg N, Berg S, et al
    Psychosocial Distress in the Early Recovery Period after Radical Prostatectomy.
    Urol Int. 2022;106:891-896.
    PubMed     Abstract available


  18. ZHANG Z, Liang C
    Recurrent Prostatic Stromal Tumor of Uncertain Malignant Potential Combined with Concurrent Prostatic Adenocarcinoma: An Unusual Case.
    Urol Int. 2022;106:974-978.
    PubMed     Abstract available


    December 2021
  19. CROCEROSSA F, Carbonara U, Parekh J, Urdaneta A, et al
    PSA and PSA Kinetics as Predictors for 18F-Fluciclovine PET/CT Positivity in Biochemically Recurrent Prostate Cancer.
    Urol Int. 2021 Dec 21:1-8. doi: 10.1159/000520684.
    PubMed     Abstract available


  20. BERG S, Tully KH, von Landenberg N, Bahlburg H, et al
    How Many Cores Should Be Sampled during Systematic Prostate Biopsy in Case of Negative Multiparametric Magnetic Resonance Imaging? Analysis of 274 Men with Clinical Suspicion of Prostate Cancer.
    Urol Int. 2021 Dec 20:1-6. doi: 10.1159/000520598.
    PubMed     Abstract available


    November 2021
  21. FLEGAR L, Baunacke M, Buerk BT, Proschmann R, et al
    Decision Regret and Quality of Life after Focal Therapy with Vascular-Targeted Photodynamic Therapy (TOOKAD(R)) for Localized Prostate Cancer.
    Urol Int. 2021 Nov 23:1-6. doi: 10.1159/000520084.
    PubMed     Abstract available


  22. VESTRIS PG, Giwerc A, Hennequin C, Goujon A, et al
    Operative and Midterm Oncological Outcome of Focal Salvage Cryotherapy for Localized Prostate Cancer.
    Urol Int. 2021 Nov 15:1-6. doi: 10.1159/000518980.
    PubMed     Abstract available


    October 2021
  23. CETIN B, Wabl CA, Gumusay O
    Optimal Treatment for Patients with Oligometastatic Prostate Cancer.
    Urol Int. 2021 Oct 26:1-10. doi: 10.1159/000519386.
    PubMed     Abstract available


  24. GUO Y, Tian Y, Deng Y, Lu C, et al
    Diagnostic Performance of [18F]-Labeled PET/CT Tracers for Lymph Node/Bone Metastasis and Biochemical Recurrence Detection in Advanced Prostate Cancer: A Meta-Analysis.
    Urol Int. 2021 Oct 13:1-19. doi: 10.1159/000518478.
    PubMed     Abstract available


    September 2021
  25. LI Y, Cheng X, Zhu JL, Luo WW, et al
    Effect of Statins on the Risk of Different Stages of Prostate Cancer: A Meta-Analysis.
    Urol Int. 2021 Sep 8:1-9. doi: 10.1159/000518164.
    PubMed     Abstract available


    August 2021
  26. SONG P, Shu M, Yang L, Di X, et al
    The Prognosis of Radical Prostatectomy, External Beam Radiotherapy plus Brachytherapy, and External Beam Radiotherapy Alone for Patients above 70 Years with Very High-Risk Prostate Cancer: A Population-Matched Study.
    Urol Int. 2021 Aug 26:1-9. doi: 10.1159/000518113.
    PubMed     Abstract available


  27. PETERS R, Stephan C, Jung K, Lein M, et al
    Comparison of PHI and PHI Density for Prostate Cancer Detection in a Large Retrospective Caucasian Cohort.
    Urol Int. 2021 Aug 25:1-6. doi: 10.1159/000517891.
    PubMed     Abstract available


    July 2021
  28. TIAN B, Chunxiang E, Xiang Y, Teng P, et al
    Long Noncoding RNA LIPE-AS1 Drives Prostate Cancer Progression by Functioning as a Competing Endogenous RNA for microRNA-654-3p and Thereby Upregulating Hepatoma-Derived Growth Factor.
    Urol Int. 2021 Jul 7:1-16. doi: 10.1159/000516676.
    PubMed     Abstract available


    June 2021
  29. FERRO M, Terracciano D, Musi G, de Cobelli O, et al
    Increased Body Mass Index Is a Risk Factor for Poor Clinical Outcomes after Radical Prostatectomy in Men with International Society of Urological Pathology Grade Group 1 Prostate Cancer Diagnosed with Systematic Biopsies.
    Urol Int. 2021 Jun 24:1-8. doi: 10.1159/000516680.
    PubMed     Abstract available


    May 2021
  30. KOPP D, Kopp J, Bernhardt E, Manka L, et al
    68Ga-Prostate-Specific Membrane Antigen Positron Emission Tomography-Computed Tomography-Based Primary Staging and Histological Correlation after Extended Pelvic Lymph Node Dissection in Intermediate-Risk Prostate Cancer.
    Urol Int. 2021 May 7:1-7. doi: 10.1159/000515651.
    PubMed     Abstract available


  31. PORCARO AB, Siracusano S, Amigoni N, Tafuri A, et al
    The Influence of Endogenous Testosterone on Incidental Prostate Cancer after Transurethral Prostate Resection.
    Urol Int. 2021 May 7:1-9. doi: 10.1159/000514391.
    PubMed     Abstract available


  32. CELIK S, Kizilay F, Yorukoglu K, Aslan G, et al
    Sextant Biopsy-Based Criteria for Clinically Insignificant Prostate Cancer Are Also Valid for the 12-Core Prostate Biopsy Scheme: A Multicenter Study of Urooncology Association, Turkey.
    Urol Int. 2021 May 5:1-9. doi: 10.1159/000513658.
    PubMed     Abstract available


    January 2021
  33. MAURER V, Stahlberg J, Schiffmann I, Marks P, et al
    Continence and Complication Rates of Artificial Urinary Sphincter Devices (AMS 800) for Parkinson and Stroke Patients with Incontinence after Prostate Surgery: Retrospective Analysis of a Prospective Database.
    Urol Int. 2021;105.
    PubMed     Abstract available


  34. SHEN Q, Zhou Z, Liu Z, Hu S, et al
    Clinical and Pathological Features of Prostatic Stromal Tumor of Uncertain Malignant Potential: A Retrospective Study of 23 Chinese Cases.
    Urol Int. 2021;105.
    PubMed     Abstract available


  35. GOSSLER C, May M, Breyer J, Stojanoski G, et al
    High BMI, Aggressive Tumours and Long Console Time Are Independent Predictive Factors for Symptomatic Lymphocele Formation after Robot-Assisted Radical Prostatectomy and Pelvic Lymph Node Dissection.
    Urol Int. 2021;105.
    PubMed     Abstract available


  36. XU B, Ma BL, Peng YJ, Zhang Q, et al
    Learning Curve of an Innovative "3-Port" Laparoscopic Radical Prostatectomy: A Single-Center Analysis from 2016 to 2019.
    Urol Int. 2021;105.
    PubMed     Abstract available


  37. SCHMITZ-DRAGER BJ, Muhlich S, Lange C, Benderska-Soder N, et al
    Effectiveness and Distribution of Testosterone Levels within First Year of Androgen Deprivation Therapy in a Real-World Setting: Results from the Non-Interventional German Cohort LEAN Study.
    Urol Int. 2021;105.
    PubMed     Abstract available


  38. APFELBECK M, Schlenker B, Chaloupka M, Stief CG, et al
    Multiparametric MRI Lesion Classified as Prostate Imaging-Reporting and Data System 5 but Histopathologically Described as Benign: A Case Report and Review of Literature.
    Urol Int. 2021;105.
    PubMed     Abstract available


  39. NAKANISHI Y, Ito M, Kataoka M, Ikuta S, et al
    Who Can Avoid Biopsy of Magnetic Resonance Imaging-Negative Lobes without Compromising Significant Cancer Detection among Men with Unilateral Magnetic Resonance Imaging-Positive Lobes?
    Urol Int. 2021;105.
    PubMed     Abstract available


  40. PRATSINIS M, Babst C, Langenauer J, Schmid HP, et al
    Qualitative Assessment of Medical Information on YouTube: A Multilingual Comparison of Common Urological Conditions.
    Urol Int. 2021;105.
    PubMed     Abstract available


  41. MASSANOVA M, Robertson S, Barone B, Dutto L, et al
    The Comparison of Imaging and Clinical Methods to Estimate Prostate Volume: A Single-Centre Retrospective Study.
    Urol Int. 2021;105.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: